Literature DB >> 6769399

Gold binding to blood cells and serum proteins during chrysotherapy.

R J van de Stadt, B Abbo-Tilstra.   

Abstract

The binding of gold to peripheral erythrocytes and serum protein fractions was studied during chrysotherapy of 1 to 2 years' duration in 43 patients with rheumatoid arthritis. In 45% of the patients more than 10% of the gold was found to be strongly bound to blood cells. 5--15% of the metal is bound to non-albumin protein fractions at serum gold concentrations larger than 2 microgram/ml. In contrast to the cellular binding of gold the relative binding of gold to non-albumin proteins was inversely proportional to the serum concentrations. Binding to neither blood cells nor to non-albumin protein fractions was found to be correlated with clinical parameters.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6769399      PMCID: PMC1000466          DOI: 10.1136/ard.39.1.31

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  19 in total

1.  Serum gold determinations in patients with rheumatoid arthritis receiving sodium aurothiomalate.

Authors:  J D Jessop; R G Johns
Journal:  Ann Rheum Dis       Date:  1973-05       Impact factor: 19.103

2.  Serum gold. II. Levels in rheumatoid arthritis.

Authors:  H M Rubinstein; A A Dietz
Journal:  Ann Rheum Dis       Date:  1973-03       Impact factor: 19.103

3.  Pharmacodynamics of 197Au and 195Au labeled aurothiomalate in blood. Correlation with course of rheumatoid arthritis, gold toxicity and gold excretion.

Authors:  N L Gottlieb; P M Smith; E M Smith
Journal:  Arthritis Rheum       Date:  1974 Mar-Apr

4.  Monitoring serum gold values to improve chrysotherapy in rheumatoid arthritis.

Authors:  A Lorber; C J Atkins; C C Chang; Y B Lee; J Starrs; R A Bovy
Journal:  Ann Rheum Dis       Date:  1973-03       Impact factor: 19.103

5.  Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis.

Authors:  D M Ritchie; J A Boyle; J M McInnes; M K Jasani; T G Dalakos; P Grieveson; W W Buchanan
Journal:  Q J Med       Date:  1968-07

6.  Gold metabolism in patients with rheumatoid arthritis treated with gold compounds--reinvestigated.

Authors:  B R Mascarenhas; J L Granda; R H Freyberg
Journal:  Arthritis Rheum       Date:  1972 Jul-Aug

7.  Clinical response and serum gold levels in chrysotherapy. Lack of correlation.

Authors:  R C Gerber; H E Paulus; R Bluestone; C M Pearson
Journal:  Ann Rheum Dis       Date:  1972-07       Impact factor: 19.103

8.  Plasma levels and urinary excretion of gold during routine treatment of rheumatoid arthritis.

Authors:  F E Krusius; A Markkanen; P Peltola
Journal:  Ann Rheum Dis       Date:  1970-05       Impact factor: 19.103

9.  Transport of gold in the body.

Authors:  E G McQueen; P W Dykes
Journal:  Ann Rheum Dis       Date:  1969-07       Impact factor: 19.103

10.  Gold kinetics following aurothiomalate therapy: use of a whole-body radiation counter.

Authors:  R C Gerber; H E Paulus; R I Jennrich; M Lederer; R Bluestone; W H Blahd; C M Pearson
Journal:  J Lab Clin Med       Date:  1974-05
View more
  9 in total

1.  Binding of sodium aurothiomalate to human serum albumin in vitro at physiological conditions.

Authors:  S M Pedersen
Journal:  Ann Rheum Dis       Date:  1986-09       Impact factor: 19.103

2.  Inhibition of lymphocyte activation by gold sodium thiomalate.

Authors:  S J Hopkins; M I Jayson; P Van der Zeil
Journal:  Br J Pharmacol       Date:  1983-06       Impact factor: 8.739

3.  Role of metallothionein in cellular uptake and disposition of gold sodium thiomalate.

Authors:  R P Sharma
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1984 Jan-Mar       Impact factor: 2.441

4.  Gold binding to red blood cells.

Authors:  G G Graham; G D Champion; T M Haavisto; P J McNaught
Journal:  Ann Rheum Dis       Date:  1981-04       Impact factor: 19.103

5.  Gold binding to blood cells.

Authors: 
Journal:  Ann Rheum Dis       Date:  1980-10       Impact factor: 19.103

Review 6.  Auranofin. A preliminary review of its pharmacological properties and therapeutic use in rheumatoid arthritis.

Authors:  M Chaffman; R N Brogden; R C Heel; T M Speight; G S Avery
Journal:  Drugs       Date:  1984-05       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics of drugs used in juvenile arthritis.

Authors:  K J Skeith; F Jamali
Journal:  Clin Pharmacokinet       Date:  1991-08       Impact factor: 6.447

8.  A double-blind study on the effect of discontinuation of gold therapy in patients with rheumatoid arthritis.

Authors:  H Van der Leeden; B A Dijkmans; J Hermans; A Cats
Journal:  Clin Rheumatol       Date:  1986-01       Impact factor: 2.980

9.  Measurement of 'free' gold in patients receiving disodium aurothiomalate and the association of high free to total gold levels with toxicity.

Authors:  M J Heath
Journal:  Ann Rheum Dis       Date:  1988-01       Impact factor: 19.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.